Qritive, a leading provider of digital pathology solutions, has announced the launch of a new AI (Artificial Intelligence) module, QAi Prostate, for prostate cancer diagnosis.

Using advanced machine learning algorithms, QAi Prostate analyses whole slide images of prostate core needle biopsies, identifies prostatic adenocarcinoma region, and segments and classifies them into benign and malignant areas.   

Prostate adenocarcinoma is the most common form of prostate cancer, accounting for approximately 90% of all prostate cases. QAi Prostate is a powerful tool that utilises both whole slide images and regions of interest (ROI) for screening adenocarcinoma.

After identifying and classifying the benign and malignant tumor areas in biopsy tissue samples, it provides a detailed summary explaining the tumor size and percentage for each slide or ROI. This helps pathologists make a more informed and accurate diagnosis quickly, thereby reducing time to treatment for patients.  

QAi Prostate was developed by the Singapore-based startup using a rich dataset and has undergone testing and validation to ensure its clinical metrics and reliability. QAi Prostate can be deployed for research use or as laboratory developed test only. It is currently not approved by the FDA or CE marked.